Heart Failure Hospital Readmissions and Physical Therapy
Completed
- Conditions
- Acute Heart Failure
- First Posted Date
- 2018-05-07
- Last Posted Date
- 2019-08-29
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 102
- Registration Number
- NCT03517514
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Clinical Trial Readiness for SCA1 and SCA3
- Conditions
- Spinocerebellar Ataxia 3Spinocerebellar Ataxia Type 1
- First Posted Date
- 2018-04-04
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 200
- Registration Number
- NCT03487367
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Mesenchymal Stromal Cells in Living Donor Kidney Transplantation
Phase 2
- Conditions
- Renal TransplantationMesenchymal Stem Cells
- Interventions
- Biological: Mesenchymal Stromal Stem Cells (MSCs) InfusionOther: Normal Saline (Placebo) Infusion
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 24
- Registration Number
- NCT03478215
- Locations
- 🇺🇸
Houston Methodist Hospital System, Houston, Texas, United States
Explore Transplant @Home Within Kaiser Permanente Southern California
Not Applicable
Active, not recruiting
- Conditions
- End Stage Renal Disease
- Interventions
- Behavioral: Patient-Guided
- First Posted Date
- 2018-01-04
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 977
- Registration Number
- NCT03389932
- Locations
- 🇺🇸
Kaiser Permanente Research and Evaluation, Pasadena, California, United States
Phase Ib of L-NMMA and Pembrolizumab
Phase 1
Active, not recruiting
- Conditions
- Non-Small Cell Lung CancerDNA Repair-Deficiency DisordersUrothelial Carcinoma BladderMalignant MelanomaClassical Hodgkin LymphomaHead and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 12
- Registration Number
- NCT03236935
- Locations
- 🇺🇸
Houston Methodist Cancer Center, Houston, Texas, United States
Deep Brain Stimulation in Patients With LUTS
Completed
- Conditions
- Bladder DysfunctionNeurogenic Bladder
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 6
- Registration Number
- NCT03202251
- Locations
- 🇺🇸
Houston Methodist Research Institute, Houston, Texas, United States
Prospective Cohort of Transitional Urology Patients
Recruiting
- Conditions
- MeningoceleBladder ExstrophySpina BifidaCloacal ExstrophyMyelomeningoceleGenitourinary Congenital Anomalies
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 200
- Registration Number
- NCT03061084
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC
Phase 2
Completed
- Conditions
- Metastatic Non-small Cell Lung CancerMetastatic Triple-negative Breast Cancer
- Interventions
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 57
- Registration Number
- NCT03004183
- Locations
- 🇺🇸
Houston Methodist Cancer Center, Houston, Texas, United States
TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer
Phase 2
Completed
- Conditions
- Estrogen Receptor Positive Breast Cancer
- Interventions
- Drug: TAK-228Drug: Tamoxifen
- First Posted Date
- 2016-12-12
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 28
- Registration Number
- NCT02988986
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸Houston Methodist Hospital Willowbrook, Houston, Texas, United States
🇺🇸Houston Methodist Hospital Sugar Land, Sugar Land, Texas, United States
L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
Phase 1
Completed
- Conditions
- Metastatic Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 37
- Registration Number
- NCT02834403
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath